阿米万他单抗治疗晚期非小细胞肺癌伴MET外显子14跳跃突变参与者的CHRYSALIS研究最终结果
CHRYSALIS研究评估阿米万他单抗在晚期MET外显子14跳跃突变非小细胞肺癌中的安全性和疗效,97例参与者中总体客观缓解率32%,初治者50%,无既往MET治疗者46%,有既往MET治疗者19%,中位缓解持续时间11.2个月,中位无进展生存期5.3个月。
要点
- 阿米万他单抗在MET外显子14跳跃突变晚期非小细胞肺癌中总体客观缓解率为32%。
- 初治参与者客观缓解率50%,无既往MET治疗者46%,有既往MET治疗者19%。
- 中位缓解持续时间11.2个月,61%(19/31)缓解者缓解持续时间≥6个月。
核心结论
- 阿米万他单抗在MET外显子14跳跃突变晚期非小细胞肺癌参与者中显示出具有临床意义且持久的抗肿瘤活性,包括既往MET治疗进展者。
- 安全性特征与阿米万他单抗在EGFR突变非小细胞肺癌中的既往报告一致。
研究设计与样本
- CHRYSALIS研究纳入MET外显子14跳跃突变非小细胞肺癌参与者,这些参与者在标准治疗后进展或拒绝标准治疗。
- 参与者接受阿米万他单抗静脉给药,前4周每周一次,之后每两周一次。
- 共97例参与者,其中16例初治,28例接受过既往治疗但未接受MET治疗,53例接受过既往MET治疗。
主要发现
- 总体客观缓解率为32%,初治参与者为50%,无既往MET治疗参与者为46%,有既往MET治疗参与者为19%。
- 在无既往MET治疗参与者中,无论是否共存基因组改变,均观察到阿米万他单抗活性。
- 总体临床获益率为69%,初治参与者为88%,无既往MET治疗参与者为64%,有既往MET治疗参与者为66%。
- 中位缓解持续时间为11.2个月,61%(19/31)的缓解者缓解持续时间大于或等于6个月。
- 中位无进展生存期为5.3个月(95%置信区间,4.3-7.0),中位总生存期为15.8个月(95%置信区间,14.6-不可估计)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity. We assessed the safety and efficacy of amivantamab in participants with advanced NSCLC harboring primary MET exon 14 skipping mutations (METex14). METHODS: CHRYSALIS enrolled participants with METex14 NSCLC who progressed after or declined standard-of-care therapy. Participants received intravenous amivantamab weekly for 4 weeks and biweekly thereafter. Objective response rate, duration of response (DoR), clinical benefit rate, progression-free survival, overall survival, safety, and circulating tumor DNA were analyzed. RESULTS: Among 97 participants, 16 were treatment naive, 28 received prior treatment without MET therapies, and 53 received prior MET therapies. Objective response rate was 32% overall, 50% in treatment-naive participants, 46% in participants without prior MET therapies, and 19% in participants with prior MET therapies. In participants without prior MET therapies, amivantamab activity was observed regardless of co-occurring genomic alterations. Clinical benefit rate was 69% overall, 88% in treatment-naive participants, 64% in participants without prior MET therapies, and 66% in participants with prior MET therapies. Median DoR was 11.2 months; 61% (19/31) of the responders had DoR greater than or equal to 6 months. Median progression-free survival was 5.3 months (95% confidence interval, 4.3-7.0); median overall survival was 15.8 months (95% confidence interval, 14.6-not estimable). Most common adverse events were rash (79%) and infusion-related reactions (72%), most being grades 1 to 2 (52%). CONCLUSIONS: The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who progressed on prior MET therapies.
引用
- Krebs MG, Cho BC, Hiret S, et al. Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. J Thorac Oncol. 2025. PMID: 40383434. doi:10.1016/j.jtho.2025.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。